Avdoralimab (anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FORCE)

Autor: Julien Carvelli, Ferhat Meziani, Jean Dellamonica, Pierre-Yves Cordier, Jerome Allardet-Servent, Megan Fraisse, Lionel Velly, Saber Barbar, Samuel Lehingue, Christophe Guervilly, Maxime Desgrouas, Fabrice Camou, Christelle Piperoglou, Frederic Vely, Robert Zerbib, Emmanuel Mitry, Joyson Karakunnel, Joanna Fares, Luciana Batista, Federico Rotolo, Julien Viotti, Agnès Boyer-Chammard, Sabrina Carpentier, Olivier Demaria, Karine Lacombe, Erwan Le Dault, Nassima Chouaki-Benmansour, michel Carles, Nicolas Schleinitz, Eric Vivier, The Force Study Group

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5473ad33e883638db63ece4b4dc27694
https://doi.org/10.2139/ssrn.4028533

Complement cascade in severe forms of COVID-19: Recent advances in therapy

Autor: Eric Vivier, Julien Carvelli, Nassima Chouaki Benmansour

Publikováno v: European Journal of Immunology
European Journal of Immunology, Wiley-VCH Verlag, 2021, pp.1-8. ⟨10.1002/eji.202048959⟩
European Journal of Immunology, 2021, pp.1-8. ⟨10.1002/eji.202048959⟩

The complement system is an essential component of the innate immune system. The three complement pathways (classical, lectin, alternative) are directly or indirectly activated by the SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e21779551ad60474bb7190a8f84954
https://hal-amu.archives-ouvertes.fr/hal-03226299/document

483 Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Autor: Olivier Demaria, Julien Carvelli, Nassima Chouaki Benmansour, Joanna Fares, Luciana Batista, Marie-Laure Thibult, Ariane Morel, Sabrina Carpentier, Romain Remark, Agnes Represa, Frederic Vely, Mikael Ebbo, Nicolas Schleinitz, Robert Zerbib, Yannis Morel, Eric Vivier

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The C5a anaphylatoxin and its receptor C5aR1 (CD88) play a key role in the initiation and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6747000b7ebd8d3baeddbe0aa49c01
https://doaj.org/article/f2d5c3645da248b48518f8ce07cb800f